- 1.
Gorman GS, Schaefer AM, Ng Y et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 2015; 77: 753–9. [PubMed][CrossRef]
- 2.
Saneto RP, Naviaux RK. Polymerase gamma disease through the ages. Dev Disabil Res Rev 2010; 16: 163–74. [PubMed][CrossRef]
- 3.
Winterthun S, Ferrari G, He L et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology 2005; 64: 1204–8. [PubMed][CrossRef]
- 4.
Hakonen AH, Heiskanen S, Juvonen V et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005; 77: 430–41. [PubMed][CrossRef]
- 5.
Hikmat O, Tzoulis C, Chong WK et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genet Med 2017; 19: 1217–25. [PubMed][CrossRef]
- 6.
Engelsen BA, Tzoulis C, Karlsen B et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008; 131: 818–28. [PubMed][CrossRef]
- 7.
Anagnostou ME, Ng YS, Taylor RW et al. Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: A clinical and molecular genetic review. Epilepsia 2016; 57: 1531–45. [PubMed][CrossRef]
- 8.
Tzoulis C, Henriksen E, Miletic H et al. No evidence of ischemia in stroke-like lesions of mitochondrial POLG encephalopathy. Mitochondrion 2017; 32: 10–5. [PubMed][CrossRef]
- 9.
Tzoulis C, Neckelmann G, Mørk SJ et al. Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain 2010; 133: 1428–37. [PubMed][CrossRef]
- 10.
Hikmat O, Naess K, Engvall M et al. Elevated cerebrospinal fluid protein in POLG-related epilepsy: Diagnostic and prognostic implications. Epilepsia 2018; 59: 1595–602. [PubMed][CrossRef]
- 11.
Van Goethem G, Schwartz M, Löfgren A et al. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet 2003; 11: 547–9. [PubMed][CrossRef]
- 12.
Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 2010; 51: 364–73. [PubMed][CrossRef]
- 13.
Hynynen J, Komulainen T, Tukiainen E et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl 2014; 20: 1402–12. [PubMed][CrossRef]
- 14.
Ng YS, van Ruiten H, Lai HM et al. The adjunctive application of transcranial direct current stimulation in the management of de novo refractory epilepsia partialis continua in adolescent-onset POLG-related mitochondrial disease. Epilepsia Open 2018; 3: 103–8. [PubMed][CrossRef]
- 15.
Hikmat O, Tzoulis C, Klingenberg C et al. The presence of anaemia negatively influences survival in patients with POLG disease. J Inherit Metab Dis 2017; 40: 861–6. [PubMed][CrossRef]
- 16.
Tzoulis C, Engelsen BA, Telstad W et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006; 129: 1685–92. [PubMed][CrossRef]
- 17.
Helse Berge. Norsk kvalitetsregister for polymerase-gamma (POLG) relatert sykdom. https://helse-bergen.no/avdelinger/nevroklinikken/nevrologisk-avdeling/norsk-kvalitetsregister-for-polymerase-gamma-polg-relatert-sykdom/ Lest 12.11.2019.
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.